LPL Financial LLC Purchases 29,043 Shares of Danaher Co. (NYSE:DHR)

LPL Financial LLC increased its position in shares of Danaher Co. (NYSE:DHR) by 9.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 353,217 shares of the conglomerate’s stock after purchasing an additional 29,043 shares during the period. LPL Financial LLC’s holdings in Danaher were worth $88,251,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Gilbert & Cook Inc. lifted its stake in Danaher by 4.9% in the 4th quarter. Gilbert & Cook Inc. now owns 1,830 shares of the conglomerate’s stock worth $423,000 after purchasing an additional 86 shares in the last quarter. Accretive Wealth Partners LLC lifted its position in shares of Danaher by 12.9% in the fourth quarter. Accretive Wealth Partners LLC now owns 3,632 shares of the conglomerate’s stock worth $840,000 after buying an additional 414 shares in the last quarter. Gryphon Financial Partners LLC boosted its stake in Danaher by 19.1% during the fourth quarter. Gryphon Financial Partners LLC now owns 2,917 shares of the conglomerate’s stock valued at $675,000 after buying an additional 468 shares during the last quarter. Jump Financial LLC grew its holdings in Danaher by 287.0% during the 4th quarter. Jump Financial LLC now owns 4,625 shares of the conglomerate’s stock valued at $1,070,000 after buying an additional 3,430 shares in the last quarter. Finally, Great Lakes Advisors LLC increased its stake in Danaher by 23.3% in the 4th quarter. Great Lakes Advisors LLC now owns 43,957 shares of the conglomerate’s stock worth $10,169,000 after acquiring an additional 8,317 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Transactions at Danaher

In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. The disclosure for this sale can be found here. Over the last three months, insiders have sold 39,659 shares of company stock valued at $11,042,433. Corporate insiders own 11.10% of the company’s stock.

Danaher Stock Up 0.6 %

Danaher stock opened at $274.25 on Friday. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The business has a fifty day moving average of $264.55 and a two-hundred day moving average of $256.49. The firm has a market cap of $198.07 billion, a P/E ratio of 46.48, a P/E/G ratio of 4.48 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter last year, the company earned $2.05 earnings per share. The firm’s revenue for the quarter was down 2.9% compared to the same quarter last year. On average, analysts forecast that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.39%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

Analyst Ratings Changes

DHR has been the subject of several research reports. Jefferies Financial Group started coverage on shares of Danaher in a research report on Monday, June 3rd. They set a “buy” rating and a $295.00 price objective for the company. Leerink Partners increased their price target on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Barclays raised their price objective on Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 24th. Finally, Stifel Nicolaus boosted their target price on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $278.94.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.